We have been specialized in exporting and importing pharmaceutical intermediates and chemical productsas well as API for more than 10+ years, covering all over world, such as USA, Canada, England, French and so on.
R & D
Fully equipped research facility to support Sandoo’s internal supply chain and to offer custom R&D services.
FACILITIES
We are supported by all kinds, including FDA approved, GMP as well as GMP like sites.
COMPLIANCE
Our facilities are designed to comply with ICH 2022 working draft guidelines for quality standards.
To be harder, faster, stronger and better, to win invaluable trust from every customer.
AUTOMATED MANUFACTURING
GAMP 5 compliant, Distributed Control System (DCS) enabled manufacturing line that provides excellent control over operating parameters to deliver consistent quality output batch over batch.
COMPLETELY BACKWARD INTEGRATED
Our manufacturing facilities are both independent as well as integrable with each other; starting from fine chemicals to advanced pharmaceutical intermediates to APIs.
RICH LEARNING ENVIRONMENT
Our employees enjoy a rich learning-oriented atmosphere, enabling them to reach global standards and become a benchmark for knowledge.
QUALITY & INTEGRITY
Our approach to quality and Integrity is transparancy. Our facilities and systems are designed based on QbD principles.
The origin of impurities in drugs is from various sources and phases if the synthetic process and preparation of pharmaceutical dosage forms. Majority of the impurities are characteristics of the synthetic route of the manufacturing process. There are several possibilities of synthesizing a drug; it is possible that the same product of different sources may give rise to different impurities.
In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.
The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials.